Phenelzine Sulfate

CHEMBL1200895 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
234.3 g/mol
LogP
Phase
4

A sulfate salt form of phenelzine with the same therapeutic properties. An older antidepressant belonging to the MAO inhibitor class, used to treat depression that has not responded to other medications, and sometimes used for anxiety disorders.

分子量

234.2800 g/mol

TPSA

121.00 Ų

治療領域

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

NNCCc1ccccc1.O=S(=O)(O)O

InChI

InChI=1S/C8H12N2.H2O4S/c9-10-7-6-8-4-2-1-3-5-8;1-5(2,3)4/h1-5,10H,6-7,9H2;(H2,1,2,3,4)

Molecular Formula

C8H14N2O4S

HBD / HBA

4 / 6

回転可能結合数

3

重原子数

15

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

A sulfate salt form of phenelzine with the same therapeutic properties. An older antidepressant belonging to the MAO inhibitor class, used to treat depression that has not responded to other medications, and sometimes used for anxiety disorders.

Yes, Phenelzine Sulfate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200895. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 61100. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.